Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging

被引:31
|
作者
Wennberg, Alexandra M. V. [1 ]
Hagen, Clinton E. [1 ]
Edwards, Kelly [1 ,4 ]
Roberts, Rosebud O. [1 ,3 ]
Machulda, Mary M. [2 ]
Knopman, David S. [3 ]
Petersen, Ronald C. [3 ]
Mielke, Michelle M. [1 ,3 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Psychol, Rochester, MN USA
[3] Mayo Clin, Dept Neurol, Rochester, MN USA
[4] St Josephs Mercy Hosp, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
cognition; metformin; type II diabetes; RECORDS-LINKAGE; METFORMIN; VITAMIN-B12; DEMENTIA; MELLITUS; DISEASE; ADULT; NORMS;
D O I
10.1002/gps.4900
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
ObjectiveTo determine the cross-sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics. MethodsWe examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging. We created propensity scores to adjust for treatment effects. We used multivariate linear and logistic regression models to investigate the cross-sectional association between treatment type and cognitive test z scores, respectively. Mixed effects models and competing risk regression models were used to determine the longitudinal association between treatment type and change in cognitive test z scores and risk of developing incident MCI. ResultsIn linear regression analyses adjusted for age, sex, education, body mass index, APOE epsilon 4, insulin treatment, medical comorbidities, number of medications, duration of diabetes, and propensity score, we did not observe an association between metformin use and cognitive test performance. Additionally, we did not observe an association between metformin use and cognitive test performance over time (median=3.7-year follow-up). Metformin was associated with an increased risk of MCI (subhazard ratio (SHR)=2.75; 95% CI=1.64, 4.63, P<.001). Similarly, other oral medications (SHR=1.96; 95% CI=1.19, 3.25; P=.009) and insulin (SHR=3.17; 95% CI=1.27, 7.92; P=.014) use were also associated with risk of MCI diagnosis. ConclusionsThese findings suggest that metformin use, as compared to management of diabetes with other treatments, is not associated with cognitive test performance. However, metformin was associated with incident MCI diagnosis.
引用
收藏
页码:1114 / 1120
页数:7
相关论文
共 50 条
  • [21] Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study
    Callisaya, Michele L.
    Beare, Richard
    Moran, Chris
    Thanh Phan
    Wang, Wei
    Srikanth, Velandai K.
    DIABETOLOGIA, 2019, 62 (03) : 448 - 458
  • [22] Early Cognitive Deficits in Type 2 Diabetes: A Population-Based Study
    Marseglia, Anna
    Fratiglioni, Laura
    Laukka, Erika J.
    Santoni, Giola
    Pedersen, Nancy L.
    Backman, Lars
    Xu, Weili
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 (03) : 1069 - 1078
  • [23] Type II Diabetes in Mild Cognitive Impairment and Alzheimer's Disease: Results from a Prospective Population-Based Study in Germany
    Toro, Pablo
    Schoenknecht, Peter
    Schroeder, Johannes
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (04) : 687 - 691
  • [24] Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes A population-based study
    Kivimaki, Mika
    Hamer, Mark
    Batty, G. David
    Geddes, John R.
    Tabak, Adam G.
    Pentti, Jaana
    Virtanen, Marianna
    Vahtera, Jussi
    DIABETES CARE, 2010, 33 (12) : 2611 - 2616
  • [25] Association between tooth loss rate and risk of mild cognitive impairment in older adults: a population-based longitudinal study
    Xu, Shuyu
    Huang, Xi
    Gong, Yin
    Sun, Jiangwei
    AGING-US, 2021, 13 (17): : 21599 - 21609
  • [26] The Association Between Diabetes Duration and Domain-Specific Cognitive Impairment: A Population-Based Study
    Tang, Xingyao
    Wang, Ying
    Simo, Rafael
    Stehouwer, Coen D. A.
    Zhou, Jian-Bo
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 90 (04) : 1435 - 1446
  • [27] Hospitalisation without delirium is not associated with cognitive decline in a population-based sample of older people-results from a nested, longitudinal cohort study
    Richardson, Sarah J.
    Lawson, Rachael
    Davis, Daniel H. J.
    Stephan, Blossom C. M.
    Robinson, Louise
    Matthews, Fiona E.
    Brayne, Carol
    Barnes, Linda E.
    Taylor, John-Paul
    Parker, Stuart G.
    Allan, Louise M.
    AGE AND AGEING, 2021, 50 (05) : 1675 - 1681
  • [28] Drugs With Anticholinergic Properties as a Risk Factor for Cognitive Impairment in Elderly People A Population-Based Study
    Cancelli, Iacopo
    Gigli, Gian Luigi
    Piani, Antonella
    Zanchettin, Barbara
    Janes, Franceso
    Rinaldi, Adriana
    Valente, Mariarosaria
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (06) : 654 - 659
  • [29] The relationship between cognitive impairment and diabetes self-management in a population-based community sample of older adults with Type 2 diabetes
    Denise G. Feil
    Carolyn W. Zhu
    David L. Sultzer
    Journal of Behavioral Medicine, 2012, 35 : 190 - 199
  • [30] The relationship between cognitive impairment and diabetes self-management in a population-based community sample of older adults with Type 2 diabetes
    Feil, Denise G.
    Zhu, Carolyn W.
    Sultzer, David L.
    JOURNAL OF BEHAVIORAL MEDICINE, 2012, 35 (02) : 190 - 199